Literature DB >> 10561000

Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study.

R Azziz1, L A Hincapie, E S Knochenhauer, D Dewailly, L Fox, L R Boots.   

Abstract

OBJECTIVE: To prospectively establish the specificity, sensitivity, and positive predictive value (PPV) of a basal 17-hydroxyprogesterone (17-HP) level for the screening of 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) among hyperandrogenic women.
DESIGN: Prospective observational trial.
SETTING: Tertiary care academic medical centers. PATIENT(S): Eight healthy controls, 20 patients with NCAH, and 284 consecutively seen patients with hyperandrogenism. INTERVENTION(S): All controls and patients with NCAH, and select patients with hyperandrogenism, underwent acute ACTH (1-24) stimulation. MAIN OUTCOME MEASURE(S): Specificity was determined by measuring 17-HP every other day during one menstrual cycle in 8 healthy women with normal ovulation (107 samples). Sensitivity was determined by measuring 17-HP between 7 and 9 A.M. and 3 and 5 P.M. on the same day in 20 patients with genetically confirmed NCAH. The PPV was determined by prospectively measuring 17-HP in 284 consecutively seen hyperandrogenic women at their initial evaluation. The diagnosis of NCAH was established by a stimulated 17-HP level of >10 ng/mL. RESULT(S): Among controls, 17-HP levels of <2, <3, and <4 ng/mL all had a specificity of 100% when obtained in the follicular phase; when obtained in the luteal phase, they had specificities of 53%, 82%, and 82%, respectively. Among patients with NCAH, 17-HP levels of >2, >3, and >4 ng/mL had sensitivities of 100%, 90%, and 90%, respectively, for the detection of the disorder when obtained in the morning, and sensitivities of 95%, 90%, and 85%, respectively, when obtained in the afternoon. Among the 284 consecutively seen hyperandrogenic women, the PPVs of the first and second 17-HP levels were 7.3% and 19% for a cutoff level of >2 ng/mL, 13% and 43% for a cutoff level of >3 ng/mL, and 33% and 40% for a cutoff level of >4 ng/mL, respectively. CONCLUSION(S): A basal 17-HP level is a useful screening tool for NCAH. A cutoff level of 4 ng/mL has maximum specificity and PPV, with little loss in sensitivity if testing is performed in the morning and during the follicular phase. However, a lower cutoff level (e.g., 2 or 3 ng/mL) is preferable if testing is performed at odd hours of the day, as is common in many practices, and maximum sensitivity is desired.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561000     DOI: 10.1016/s0015-0282(99)00383-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  36 in total

Review 1.  Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment.

Authors:  D Merke; M Kabbani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome.

Authors:  Maryam Saghafi-Asl; Saeed Pirouzpanah; Mehranghiz Ebrahimi-Mameghani; Mohammad Asghari-Jafarabadi; Soudabeh Aliashrafi; Bita Sadein
Journal:  Health Promot Perspect       Date:  2013-12-31

3.  Sympathetic arousal increases a negative memory bias in young women with low sex hormone levels.

Authors:  Shawn E Nielsen; Sarah J Barber; Audrey Chai; David V Clewett; Mara Mather
Journal:  Psychoneuroendocrinology       Date:  2015-08-04       Impact factor: 4.905

4.  Comparison of two isometric handgrip protocols on sympathetic arousal in women.

Authors:  Shawn E Nielsen; Mara Mather
Journal:  Physiol Behav       Date:  2015-01-28

5.  Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families.

Authors:  Radha Nandagopal; Ninet Sinaii; Nilo A Avila; Carol Van Ryzin; Wuyan Chen; Gabriela P Finkielstain; Sneha P Mehta; Nazli B McDonnell; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2011-03-28       Impact factor: 6.664

6.  Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.

Authors:  Cindy T Pau; Candace Keefe; Jessica Duran; Corrine K Welt
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

7.  Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome.

Authors:  Uche Ezeh; Bulent O Yildiz; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

8.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

9.  A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

Review 10.  Nonclassic adrenal hyperplasia.

Authors:  Phyllis W Speiser
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.